Patient-friendly summary
If you read nothing else
Bottom line
Multiple drug and non-drug treatments can help manage fibromyalgia symptoms, but the best results come from an individualized, multidisciplinary plan, and several newer options still need more long-term research.
Moderate evidencePublished
Evidence hierarchy
Study participants
Adults (18 years and older) diagnosed with fibromyalgia syndrome
Study Summary
This systematic narrative review surveys current and recently emerging treatments for fibromyalgia, a chronic widespread pain disorder of elusive cause that the authors note predominantly affects women. Drawing on studies published between 2000 and 2023, it groups options into pharmacological agents (SNRIs such as milnacipran and duloxetine, anticonvulsants such as pregabalin, plus newer or investigational agents including mirogabalin, lacosamide, cannabinoids, tropisetron, and sodium oxybate) and non-pharmacological strategies (cognitive-behavioral therapy, aerobic and resistance exercise, mind-body therapies, acupuncture, TENS, hydrotherapy, and others). The authors conclude that fibromyalgia requires a multidisciplinary, individualized approach combining drug and non-drug interventions, and that several recent options show promise for reducing pain and fatigue and improving quality of life. They emphasize that there is no known cure and that many newer agents still need further long-term study.
Key Findings
| Finding | Detail | Impact |
|---|---|---|
| Fibromyalgia is best managed with a multidisciplinary, individualized plan combining drug and non-drug therapies | The review concludes there is no single cure and that combining pharmacological and non-pharmacological interventions, tailored to the individual and supported by patient education and early intervention, offers the best outcomes. | High |
| FDA-approved SNRIs (milnacipran, duloxetine) reduced pain and related symptoms versus placebo in cited trials | Milnacipran at 100 and 200 mg/day improved pain and other symptoms (Clauw et al.); duloxetine at 60, 90, and 120 mg/day improved pain, sleep, mood, stiffness, fatigue, and functioning. Both were reported as generally well-tolerated, with adverse effects such as nausea and headache reported as rare. | High |
| Anticonvulsants, especially FDA-approved pregabalin, reduced pain and sleep disturbance | Pregabalin 450 mg/day reduced pain, improved sleep, and reduced fatigue versus placebo, with dizziness and somnolence as the most common dose-dependent adverse events. Mirogabalin and lacosamide showed benefit in individual trials but are described as needing further study. | Medium |
| Several non-pharmacological therapies showed positive outcomes in cited studies | Cognitive-behavioral therapy, aerobic and resistance exercise, mindfulness-based stress reduction, acupuncture, TENS, low-level laser therapy, hydrotherapy/aquatic exercise, yoga, tai chi, music therapy, and massage were each reported to reduce pain and/or fatigue and improve function or quality of life. Graded exercise therapy improved function but the authors note it may increase pain in some patients. | Medium |
| Investigational and emerging agents show promise but require more evidence | Cannabinoids (THC/CBD), tropisetron (a 5-HT3 antagonist), and sodium oxybate reduced pain/fatigue/sleep disturbance in cited studies, but the authors caution about side effects, legal restrictions (cannabinoids), and the need for further long-term safety and efficacy research. | Medium |
The review concludes there is no single cure and that combining pharmacological and non-pharmacological interventions, tailored to the individual and supported by patient education and early intervention, offers the best outcomes.
Milnacipran at 100 and 200 mg/day improved pain and other symptoms (Clauw et al.); duloxetine at 60, 90, and 120 mg/day improved pain, sleep, mood, stiffness, fatigue, and functioning. Both were reported as generally well-tolerated, with adverse effects such as nausea and headache reported as rare.
Pregabalin 450 mg/day reduced pain, improved sleep, and reduced fatigue versus placebo, with dizziness and somnolence as the most common dose-dependent adverse events. Mirogabalin and lacosamide showed benefit in individual trials but are described as needing further study.
Cognitive-behavioral therapy, aerobic and resistance exercise, mindfulness-based stress reduction, acupuncture, TENS, low-level laser therapy, hydrotherapy/aquatic exercise, yoga, tai chi, music therapy, and massage were each reported to reduce pain and/or fatigue and improve function or quality of life. Graded exercise therapy improved function but the authors note it may increase pain in some patients.
Cannabinoids (THC/CBD), tropisetron (a 5-HT3 antagonist), and sodium oxybate reduced pain/fatigue/sleep disturbance in cited studies, but the authors caution about side effects, legal restrictions (cannabinoids), and the need for further long-term safety and efficacy research.
Strengths
- Predefined PICOSTL inclusion criteria aligned to the research question
- Conducted under PRISMA guidelines and prospectively registered in PROSPERO (CRD42023421154)
- Comprehensive multi-database search (PubMed, MEDLINE, Scopus, Web of Science, Embase) plus reference-list searching
- Quality and bias appraised with established tools (Cochrane risk-of-bias, Joanna Briggs Institute, GRADE) by independent reviewers
- Covers a broad spectrum of both pharmacological and non-pharmacological interventions, including emerging agents and future research directions
Limitations
- English-language-only inclusion may have introduced language and publication bias
- Included studies used heterogeneous outcome measures, limiting direct comparison of treatments
- Some included studies had small sample sizes, limiting generalizability
- Studies varied widely in design, sample size, and intervention type (heterogeneity), limiting firm conclusions
- As a narrative synthesis, no pooled quantitative effect estimates are reported and the number of included studies is not stated in the text
Key Takeaways for Patients
What This Means for You
- 01Fibromyalgia has no cure, but a combination of treatments tailored to you can meaningfully reduce pain and fatigue and improve quality of life.
- 02Doctors may prescribe medicines such as duloxetine, milnacipran, or pregabalin, which have shown they can ease pain and improve sleep and function for many people.
- 03Non-drug approaches matter too: regular exercise (such as aerobic and strength training), cognitive-behavioral therapy, and mind-body practices like yoga and tai chi have all helped in studies.
- 04The best results usually come from a multidisciplinary plan that combines several treatments, includes patient education, and is adjusted over time with your input.
- 05Some newer options (such as cannabinoids) may help but carry side effects and legal restrictions, so discuss them with your healthcare provider.